Publication

A meta-analysis on salvage surgery as a potentially curative procedure in patients with isolated local recurrent or persistent esophageal cancer after chemoradiotherapy

Faiz, Z., Dijksterhuis, W. P. M., Burgerhof, J. G. M., Muijs, C. T., Mul, V. E. M., Wijnhoven, B. P. L., Smit, J. K. & Plukker, J. T. M., Jun-2019, In : European Journal of Surgical Oncology. 45, 6, p. 931-940 10 p.

Research output: Contribution to journalReview articleAcademicpeer-review

Copy link to clipboard

Documents

  • A meta-analysis on salvage surgery as a potentially curative procedure in patients with isolated local recurrent or persistent esophageal cancer after chemoradiotherapy.

    Final author's version, 1 MB, PDF document

    Embargo ends: 17/05/2020

    Request copy

  • A meta-analysis on salvage surgery as a potentially curative procedure in patients with isolated local recurrent or persistent esophageal cancer after chemoradiotherapy

    Final publisher's version, 463 KB, PDF document

    Request copy

DOI

Background: Isolated local recurrent or persistent esophageal cancer (EC) after curative intended definitive (dCRT) or neoadjuvant chemoradiotherapy (nCRT) with initially omitted surgery, is a potential indication for salvage surgery. We aimed to evaluate safety and efficacy of salvage surgery in these patients.

Material and methods: A systematic literature search following PRISMA guidelines was performed using databases of PubMed/Medline. All included studies were performed in patients with persistent or recurrent EC after initial treatment with dCRT or nCRT, between 2007 and 2017. Survival analysis was performed with an inverse-variance weighting method.

Results: Of the 278 identified studies, 28 were eligible, including a total of 1076 patients. Postoperative complications after salvage esophagectomy were significantly more common among patients with isolated persistent than in those with locoregional recurrent EC, including respiratory (36.6% versus 22.7%; difference in proportion 10.9 with 95% confidence interval (CI) [3.1; 18.7]) and cardiovascular complications (10.4% versus 4.5%; difference in proportion 5.9 with 95% CI [1.5; 10.2]). The pooled estimated 30-and 90-day mortality was 2.6% [1.6; 3.6] and 8.0% [6.3; 9.8], respectively. The pooled estimated 3-year and 5-year overall survival (OS) were 39.0% (95% CI: [35.8; 42.2]) and 19.4% [95% CI:16.5; 22.4], respectively. Patients with isolated persistent or recurrent EC after initial CRT had similar 5-year OS (14.0% versus 19.7%, difference in proportion -5.7, 95% CI [-13.7; 2.3]).

Conclusions: Salvage surgery is a potentially curative procedure in patients with locally recurrent or persistent esophageal cancer and can be performed safely after definitive or neoadjuvant chemoradiotherapy when surgery was initially omitted. (C) 2018 Elsevier Ltd, BASO similar to The Association for Cancer Surgery, and the European Society of Surgical Oncology. All rights reserved.

Original languageEnglish
Pages (from-to)931-940
Number of pages10
JournalEuropean Journal of Surgical Oncology
Volume45
Issue number6
Publication statusPublished - Jun-2019

    Keywords

  • Esophageal cancer, Salvage esophagectomy, Definitive chemoradiotherapy, SQUAMOUS-CELL CARCINOMA, PHASE-III TRIAL, DEFINITIVE CHEMORADIATION, CLINICAL-SIGNIFICANCE, NEOADJUVANT CHEMORADIOTHERAPY, RADIATION-THERAPY, DECLINED SURGERY, RANDOMIZED-TRIAL, DOSE RADIATION, RADIOTHERAPY

View graph of relations

ID: 67680904